These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 21978572)

  • 1. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
    Gordon KB; Papp KA; Langley RG; Ho V; Kimball AB; Guzzo C; Yeilding N; Szapary PO; Fakharzadeh S; Li S; Hsu MC; Reich K
    J Am Acad Dermatol; 2012 May; 66(5):742-51. PubMed ID: 21978572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
    Lebwohl M; Leonardi C; Griffiths CE; Prinz JC; Szapary PO; Yeilding N; Guzzo C; Li S; Hsu MC; Strober B
    J Am Acad Dermatol; 2012 May; 66(5):731-41. PubMed ID: 21930328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
    Reich K; Papp KA; Griffiths CE; Szapary PO; Yeilding N; Wasfi Y; Ott E; Hsu MC; Lebwohl M; Gordon KB;
    J Drugs Dermatol; 2012 Mar; 11(3):300-12. PubMed ID: 22395580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
    Papp KA; Griffiths CE; Gordon K; Lebwohl M; Szapary PO; Wasfi Y; Chan D; Hsu MC; Ho V; Ghislain PD; Strober B; Reich K; ; ;
    Br J Dermatol; 2013 Apr; 168(4):844-54. PubMed ID: 23301632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.
    Reich K; Langley RG; Lebwohl M; Szapary P; Guzzo C; Yeilding N; Li S; Hsu MC; Griffiths CE
    Br J Dermatol; 2011 Apr; 164(4):862-72. PubMed ID: 21332467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.
    Lebwohl M; Yeilding N; Szapary P; Wang Y; Li S; Zhu Y; Reich K; Langley RG; Papp KA
    J Am Acad Dermatol; 2010 Oct; 63(4):571-9. PubMed ID: 20599293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
    Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
    Igarashi A; Kato T; Kato M; Song M; Nakagawa H;
    J Dermatol; 2012 Mar; 39(3):242-52. PubMed ID: 21955098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2.
    Reich K; Schenkel B; Zhao N; Szapary P; Augustin M; Bourcier M; Guenther L; Langley RG
    J Dermatolog Treat; 2011 Dec; 22(6):337-47. PubMed ID: 21034290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
    Tsai TF; Ho V; Song M; Szapary P; Kato T; Wasfi Y; Li S; Shen YK; Leonardi C;
    Br J Dermatol; 2012 Nov; 167(5):1145-52. PubMed ID: 22803615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
    Menter A; Reich K; Gottlieb AB; Bala M; Li S; Hsu MC; Guzzo C; Diels J; Gelfand JM
    J Drugs Dermatol; 2008 Dec; 7(12):1137-46. PubMed ID: 19137767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
    Leonardi CL; Kimball AB; Papp KA; Yeilding N; Guzzo C; Wang Y; Li S; Dooley LT; Gordon KB;
    Lancet; 2008 May; 371(9625):1665-74. PubMed ID: 18486739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM
    J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis.
    Tan JY; Li S; Yang K; Ma B; Chen W; Zha C; Zhang J
    J Dermatolog Treat; 2011 Dec; 22(6):323-36. PubMed ID: 20923370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Langley RG; Feldman SR; Han C; Schenkel B; Szapary P; Hsu MC; Ortonne JP; Gordon KB; Kimball AB
    J Am Acad Dermatol; 2010 Sep; 63(3):457-65. PubMed ID: 20462664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
    Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
    Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
    Kimball AB; Papp KA; Wasfi Y; Chan D; Bissonnette R; Sofen H; Yeilding N; Li S; Szapary P; Gordon KB;
    J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1535-45. PubMed ID: 23279003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M; Papp K; Han C; Schenkel B; Yeilding N; Wang Y; Krueger GG
    Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.
    Pan F; Brazier NC; Shear NH; Jivraj F; Schenkel B; Brown R
    Value Health; 2011; 14(5):652-6. PubMed ID: 21839402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.